Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting
RM Navari, M Aapro - New England Journal of Medicine, 2016 - Mass Medical Soc
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Chemotherapy-induced nausea and vomiting
PJ Hesketh - New England Journal of Medicine, 2008 - Mass Medical Soc
New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a
better understanding of patients at risk, and the availability of new antiemetic agents have all …
better understanding of patients at risk, and the availability of new antiemetic agents have all …
Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus …
F Roila, J Herrstedt, M Aapro, RJ Gralla… - Annals of …, 2010 - annalsofoncology.org
Despite the relevant progress achieved in the last 20 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
MG Kris, PJ Hesketh, MR Somerfield… - Journal of clinical …, 2006 - ascopubs.org
Purpose To update the 1999 American Society of Clinical Oncology guideline for
antiemetics in oncology. Update Methodology The Update Committee completed a review …
antiemetics in oncology. Update Methodology The Update Committee completed a review …
Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics: Perception versus reality
SM Grunberg, RR Deuson, P Mavros… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND The authors determined the incidence of acute and delayed chemotherapy‐
induced nausea and emesis (vomiting)(CINV) among patients receiving highly (HEC) or …
induced nausea and emesis (vomiting)(CINV) among patients receiving highly (HEC) or …
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double …
M Saito, K Aogi, I Sekine, H Yoshizawa… - The lancet …, 2009 - thelancet.com
Background Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT 3)-receptor
antagonist that has shown better efficacy than ondansetron and dolasetron in preventing …
antagonist that has shown better efficacy than ondansetron and dolasetron in preventing …
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic …
DG Warr, PJ Hesketh, RJ Gralla, HB Muss… - Journal of Clinical …, 2005 - ascopubs.org
Purpose This is the first study in which the NK1-receptor antagonist, aprepitant (APR), was
evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with …
evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with …
[HTML][HTML] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following …
MS Aapro, SM Grunberg, GM Manikhas, G Olivares… - Annals of oncology, 2006 - Elsevier
Background: This pivotal phase III trial evaluated the efficacy and safety of palonosetron in
preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following …
preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) following …
[HTML][HTML] Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following …
PJ Hesketh, G Rossi, G Rizzi, M Palmas, A Alyasova… - Annals of …, 2014 - Elsevier
Background NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly
selective neurokinin-1 (NK 1) receptor antagonist (RA) and palonosetron (PALO), a …
selective neurokinin-1 (NK 1) receptor antagonist (RA) and palonosetron (PALO), a …
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice
K Jordan, R Gralla, F Jahn, A Molassiotis - European journal of …, 2014 - Elsevier
Over the past decades major improvements in the management of chemotherapy induced
nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV …
nausea and vomiting (CINV) were obtained. With the correct use of antiemetic drugs, CINV …